Evidence map›Paper›PMID 40341969›Full record

ReviewInternational journal of molecular medicine2025

Application of liquid biopsy in differentiating lung cancer from benign pulmonary nodules (Review).

Mingcheng Peng, Jun Gong, Taixue An, Hongbing Cheng, Liangji Chen, Mengyang Cai, Jinhua Lan, Yueting Tang

Abstract readReview
In one paragraph

Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mingcheng Peng *Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Jun Gong *Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Taixue AnDepartment of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Hongbing ChengDepartment of Thoracic Surgery, Xiantao First People's Hospital, Xiantao, Hubei 433099, P.R. China.
Liangji ChenDepartment of Clinical Laboratory, Xiantao First People's Hospital, Xiantao, Hubei 433099, P.R. China.
Mengyang CaiDepartment of Clinical Laboratory, Xiantao First People's Hospital, Xiantao, Hubei 433099, P.R. China.
Jinhua LanDepartment of Clinical Laboratory, Xiantao First People's Hospital, Xiantao, Hubei 433099, P.R. China.
Yueting TangDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diagnosis of malignant and benign pulmonary nodules has always been a prominent research topic. Accurately distinguishing between these types of lesions, particularly small or ground glass nodules, is crucial for the early detection and proactive treatment of lung cancer, ultimately leading to improved patient survival. Although various imaging methods and tissue biopsies have advanced the diagnostic efficacy of pulmonary nodules, each approach possesses inherent limitations. In recent years, there has been a growing interest in liquid biopsy as a non‑invasive and easily obtainable alternative. Furthermore, in‑depth investigations into the mechanisms underlying tumor initiation and progression have contributed to the development of circulating biomarkers for monitoring treatment response and efficacy in lung cancer. This review provides a comprehensive overview of the current landscape of pulmonary nodule diagnosis while highlighting the latest advancements in liquid biopsy techniques, such as extracellular vesicles, tumor‑educated platelets, non‑coding RNA, circulating tumor DNA and circulating antibodies.

Indexed as

Lung NeoplasmsMultiple Pulmonary NodulesSolitary Pulmonary NoduleBiomarkers, TumorDiagnosis, DifferentialHumansLiquid BiopsyBiomarkers, Tumorcirculating antibodiescirculating biomarkercirculating tumor DNAextracellular vesiclesliquid biopsylung cancernon‑coding RNApulmonary nodulestumor‑educated platelets

Identifiers

PMID40341969
PMCPMC12101102

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.